Citius Pharmaceuticals
CTXR
11 hedge funds and large institutions have $434K invested in Citius Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
57% more funds holding
Funds holding: 7 → 11 (+4)
0.13% less ownership
Funds ownership: 0.2% → 0.06% (-0.13%)
64% less capital invested
Capital invested by funds: $1.21M → $434K (-$774K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$112K |
| 2 |
Renaissance Technologies
New York
|
+$111K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.69K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$6.54K |
| 5 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$5.73K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$756K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $100K | +$111K | +2,333 | New |
|
|
AC
2
Armistice Capital
New York
| $100K | +$112K | +2,337 | New |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $90K | +$6.69K | +140 | +7% |
|
|
MIM
4
Miller Investment Management
West Conshohocken,
Pennsylvania
| $68K | – | – | – |
|
5
Dimensional Fund Advisors
Austin,
Texas
| $24K | – | – | – |
|
|
RJA
6
Raymond James & Associates
St Petersburg,
Florida
| $21K | – | – | – |
|
|
SM
7
Sabby Management
Miami Beach,
Florida
| $20K | -$756K | -15,824 | -97% |
|
|
8
Bank of America
Charlotte,
North Carolina
| $6K | +$6.54K | +137 | New |
|
|
LTFS
9
Ladenburg Thalmann Financial Services
Miami,
Florida
| $5K | +$5.73K | +120 | New |
|
|
10
UBS Group
Zurich,
Switzerland
| – | -$6K | -103 | Closed |
|
11
Morgan Stanley
New York
| – | +$48 | +1 | +100% |
|
12
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | +$430 | +9 | New |
|
CTXR Hedge Fund Activity: Q3 2018 in Review
11 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q3 2018, worth a combined $434K — down 64% from $1.21M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CTXR positions and 1 closed out — a net gain of 4 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $112K. The largest seller was Sabby Management, cutting an estimated $756K.
- 11 institutional investors held Citius Pharmaceuticals (CTXR) as of Q3 2018, up from 7 in Q2 2018.
- Funds reported $434K of Citius Pharmaceuticals stock for Q3 2018, down 64% quarter-over-quarter.
- 5 funds opened new Citius Pharmaceuticals positions in Q3 2018 and 1 closed out, a net change of +4 holders.
- The largest Citius Pharmaceuticals buyer in Q3 2018 was Armistice Capital, an estimated $112K added.
- The largest Citius Pharmaceuticals seller in Q3 2018 was Sabby Management, an estimated $756K sold.
Based on aggregated 13F filings for Q3 2018.